Advancing the global public health agenda for NAFLD: a consensus statement
Open accessThe DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease with a substantial burden worldwide. In this Consensus Statement, a global multidisciplinary group of experts develop consensus statements and recommendations addressing a broad range of topics on NAFLD to raise awareness and spur action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citation2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationExpanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Research works printed but not linked: 2
- Lazarus, J. V. et al. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge? Int. Liver Congr. 75 (Suppl. 2), 23–26 (2021).
- Grime, M. M. & Wright, G. in Wiley StatsRef: Statistics Reference Online 1–6 (Wiley, 2011).
Cited by
Items 101–200 of 807
Vogli, S., Naska, A., Marinos, G., Kasdagli, M., & Orfanos, P. (2023) · Nutrients · doi:10.3390/nu15173733 · Cited by 55
“of cirrhosis in adults and NASH-related cirrhosis is currently the second indication for liver transplantation in the United States [6,7].”
BackgroundInfluentialPrebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease
Mijangos-Trejo, A., Nuño‐Lámbarri, N., Barbero-Becerra, V. J., Uribe-Esquivel, M., Vidal‐Cevallos, P., & Chávez-Tapia, N. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914918 · Cited by 54
“NAFLD affects 20–25% of the adult population, and it is estimated that 20% develop steatohepatitis [1].”
BackgroundGolabi, P., Owrangi, S., & Younossi, Z. M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17833 · Cited by 64
Self-citationWang, Y., Chen, S., Tian, C., Wang, Q., Yang, Z., Che, W., Li, Y., & Luo, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1415484 · Cited by 60
“Currently, there are no specifically approved drugs for the treatment of MASLD, so lifestyle changes and managing risk factors are the primary treatments for people with MASLD (2).”
BackgroundJawad, M. Y., Meshkat, S., Tabassum, A., Mckenzie, A., Vincenzo, J. D. D., Guo, Z., Musavi, N. B., Phan, L., Ceban, F., Kwan, A. T. H., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852922001043 · Cited by 55
“6 Overarchingly, the highly comorbid, insidious, and prevalent nature of NAFLD makes it a significant healthcare concern.”
BackgroundThe Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021)
Danpanichkul, P., Suparan, K., Díaz, L. A., Fallon, M. B., Chen, V. L., Namsathimaphorn, K., Rakwong, K., Inkongngam, T., Kaeosri, C., Kalligeros, M., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70072 · Cited by 56
Self-citationLiver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement
Díaz, L. A., Ayares, G., Arnold, J., Idalsoaga, F. J., Corsi, Ó., Arrese, M. A., & Arab, J. P. (2022) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-022-00382-1 · Cited by 56
“These opportunities are well described in the literature and validated in several regions worldwide [7, 8].”
BackgroundSelf-citationProgressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
Ramai, D., Facciorusso, A., Vigandt, E., Schaf, B., Saadedeen, W., Chauhan, A., di Nunzio, S., Shah, A., Giacomelli, L., & Sacco, R. (2021) · Cells · doi:10.3390/cells10123401 · Cited by 54
Armandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 53
Self-citationLazarus, J. V., Castéra, L., Mark, H. E., Allen, A. M., Adams, L. A., Anstee, Q. M., Arrese, M. A., Alqahtani, S. A., Bugianesi, E., Colombo, M., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100596 · Cited by 56
“Our data come from an opportunistic sample of clinicians and researchers engaged in a previous study, 9 and while there were primary care clinicians in this sample, we received no response from this setting.”
Self-citationZhou, T., Cao, L., Du, Y., Qin, L., Lu, Y., Zhang, Q., He, Y., & Tan, D. (2023) · PeerJ · doi:10.7717/peerj.15225 · Cited by 53
Țâru, M.-G., Leucuta, D.-C., Lupșor‐Platon, M., Turco, L., Ferri, S., Hashim, A., Orasan, O. H., Procopeț, B., Ştefănescu, H., Morelli, M. C., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001190 · Cited by 51
Yang, Z., Li, A., Jiang, Y., Maidaiti, X., Wu, Y., & Jin, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-72795-0 · Cited by 57
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Self-citationKanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
Self-citationExtrahepatic morbidities and mortality of NAFLD : an umbrella review of meta‐analyses
Yi, M., Peng, W. J., Xi, F., Teng, F., Tang, Y., Kong, Q., & Chen, Z. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17165 · Cited by 49
Martínez‐Domínguez, S. J., García, S. G., Gargallo-Puyuelo, C. J., Llera, B. G., Callau, P., Mendi, C., Arroyo, M., Simón-Marco, M. Á., Ampuero, J., & Gomollón, F. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad175 · Cited by 45
Noureddin, M., Khan, S. M., Portell, F. R., Jorkasky, D. K., Dennis, J., Khan, O., Johansson, L., Johansson, E., & Sanyal, A. J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00198-x · Cited by 46
Wang, M., Chang, M., Shen, P.-P., Wei, W., Li, H., & Shen, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01954-5 · Cited by 46
“Non-alcoholic fatty liver disease (NAFLD) is a chronic condition that is becoming more prevalent globally, with approximately 25% of adults worldwide being affected [1, 2].”
BackgroundNon-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
Kosmalski, M., Śliwińska, A., & Drzewoski, J. (2023) · Biomedicines · doi:10.3390/biomedicines11041097 · Cited by 42
The burden of liver disease in Latin America
Díaz, L. A., Villota‐Rivas, M., Francisco Barrera, M., Lazarus, J. V., & Arrese, M. A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101175 · Cited by 53
Self-citationLiang, Y., Zhang, R., Biswas, S., Bu, Q., Xu, Z., Qiao, L., Zhou, Y., Tang, J., Zhou, J., Zhou, H., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13576 · Cited by 44
Han, Y., Li, L., & Wang, B. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0960-z · Cited by 44
Manzano-Núñez, R., Rivera‐Esteban, J., Navarro, J., Bañares, J., Sena, E., Schattenberg, J. M., Lazarus, J. V., Curran, A., & Pericàs, J. M. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26072 · Cited by 45
“Targeted screening programmes and prevention strategies focusing on PLHIV are needed, as part of comprehensive care provision [16, 69, 70].”
BackgroundSelf-citationDing, Z., Wei, Y., Peng, J., Wang, S., Chen, G., & Sun, J. (2023) · Biomedicines · doi:10.3390/biomedicines11102711 · Cited by 46
“MASLD is a new term that replaces nonalcoholic fatty liver disease (NAFLD), since factors related to metabolic dysfunction are a more accurate descriptor than the term “nonalcoholic” [7].”
BackgroundThyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
Self-citationA public health perspective on mitigating the global burden of chronic liver disease
Balakrishnan, M., & Rehm, J. T. (2023) · Hepatology · doi:10.1097/hep.0000000000000679 · Cited by 45
“The public health strategy to manage SLD related to metabolic dysfunction and alcohol is comparably more nascent, [8] with recent calls for greater attention and coordinated action.”
BackgroundZhou, X., Fan, Q.-Y., Byrne, C. D., Targher, G., Muthiah, M. D., Huang, D. Q., Chen, Q., Noureddin, M., Li, W., Ratziu, V., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-337431 · Cited by 44
Self-citationFeng, X., Lin, Y., Zhuo, S., Dong, Z., Shao, C., Ye, J., & Zhong, B. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.02.008 · Cited by 47
Hadefi, A., Arvanitakis, M., Trépo, E., & Zelber‐Sagi, S. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12443 · Cited by 44
“The rising global burden of NAFLD parallels the increasing prevalence of type 2 diabetes mellitus (T2DM) and obesity, resulting in high healthcare resource utilization and costs.(5,6) NAFLD is a spectrum of liver diseases ranging from liver steatosis to non‐alcoholic steatohepatitis (NASH), and fibrosis, which may lea…”
BackgroundSelf-citationDietary Modulation of Metabolic Health: From Bioactive Compounds to Personalized Nutrition
Leziak, A., Lipina, J., Reclik, M., & Kocełak, P. (2025) · Metabolites · doi:10.3390/metabo15090624 · Cited by 44
“Given the escalating burden of obesity-related, non-communicable diseases such as T2D [20], cardiovascular disease [21], and metabolic-associated fatty liver disease (MAFLD) [22], identifying dietary strategies to enhance metabolic outcomes is paramount.”
A multistakeholder approach to innovations in NAFLD care
Schattenberg, J. M., Allen, A. M., Jarvis, H., Zelber‐Sagi, S., Cusi, K., Dillon, J. F., Caussy, C., Francque, S., Younossi, Z. M., Alkhouri, N., et al. (2023) · Communications Medicine · doi:10.1038/s43856-022-00228-y · Cited by 41
Self-citationPreventive mechanisms of Chinese Tibetan medicine Triphala against nonalcoholic fatty liver disease
Jiang, Y., Zhao, L., Ma, J., Yang, Y., Zhang, B., Xu, J., Dhondrup, R., Wong, T. W., & Zhang, D. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155229 · Cited by 41
Lu, R., Liu, Y., & Hong, T. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15014 · Cited by 40
“In the current Chinese guidelines, lifestyle interventions and weight management are the first-line therapies for NAFLD, which are consistent with the globally followed guidelines or consensus.(59,60) Angiotensin-receptor blockers, statins, omega-3 polyunsaturated fatty acids, metformin and pioglitazone can be used to…”
BackgroundHeme oxygenase 1 alleviates nonalcoholic steatohepatitis by suppressing hepatic ferroptosis
Yuan, X., Li, L., Zhang, Y., Ai, R., Li, D., Dou, Y., Hou, M., Zhao, D., Zhao, S., & Nan, Y. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01855-7 · Cited by 39
“Introduction Nonalcoholic fatty liver disease (NAFLD), which affects approximately 25% of adults worldwide, is the most predominant cause of chronic liver disease at present and has emerged as a significant public health issue [1].”
BackgroundBoeckmans, J., Prochaska, J. H., Gieswinkel, A., Böhm, M., Wild, P. S., & Schattenberg, J. M. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101153 · Cited by 41
“1,8 Screening for advanced hepatic fi brosis in metabolically-compromised patients using non-invasive tests (NITs), as recommended by current guidelines, is hence complicated when accompanied by HF. 9,10 The fi brosis-4 (FIB-4) index is the recommended fi rst-line screening test and has been explored…”
Self-citationThe global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges
Chew, N., Mehta, A., Goh, R. J. L., Koh, J., Chen, Y., Chong, B., Chan, M. Y., Khan, M. S., Muthiah, M. D., Butler, J., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01220-4 · Cited by 46
Plasma proteomic signature of fatty liver disease: The Rotterdam Study
Abozaid, Y. J., Ayada, I., van Kleef, L. A., Vallerga, C. L., Pan, Q., Brouwer, W. P., Ikram, M. A., van Meurs, J. B. J., de Knegt, R. J., & Ghanbari, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000300 · Cited by 41
“[3–5] Despite the high prevalence and enormous disease burden, the understanding of protein expression in FLD and fibrosis is limited, as well as their potential as biomarkers to facilitate early detection.[6,7] Proteomics is a powerful tool for examining differences in protein expression.”
BackgroundTan, D. J. H., Chan, K. E., Wong, Z. Y., Ng, C. H., Xiao, J., Lim, W. H., Tay, P. W. L., Tang, A. S. P., Fu, C. E., Muthiah, M. D., et al. (2023) · Digestive Diseases · doi:10.1159/000533946 · Cited by 42
“Public health policies targeted at maintenance of overall metabolic health and with an emphasis on weight reduction to maintain BMI within a normal range are required at global and regional levels to combat the metabolic risk factors for NASH [29, 30].”
BackgroundSelf-citationSu, Y., Chien, K., Yang, S., Chia, W., Chen, J., & Chen, Y. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4862 · Cited by 37
“Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases([8]) and usually develops in people with metabolic abnormalities, such as a high body mass index (BMI) and insulin resistance.”
BackgroundPark, M., Kim, H., Kim, M. G., Kim, K., & Choi, K. M. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0330 · Cited by 38
Aizenshtadt, A., Wang, C., Abadpour, S., Menezes, P. D., Wilhelmsen, I., Dalmao‐Fernández, A., Stokowiec, J., Golovin, A., Johnsen, M., Combriat, T. M. D., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303785 · Cited by 39
Jinato, T., Chayanupatkul, M., Dissayabutra, T., Chutaputti, A., Tangkijvanich, P., & Chuaypen, N. (2022) · Nutrients · doi:10.3390/nu14142921 · Cited by 39
“Moreover, it has become apparent that the clinical manifestations of NAFLD are beyond the liver, such as cardiovascular disease (CVD), chronic kidney disease (CKD) and extrahepatic malignancies [3].”
BackgroundZhou, X., Chen, Q., Targher, G., Byrne, C. D., Shapiro, M. D., Tian, N., Xiao, T., Sung, K., Lip, G. Y. H., & Zheng, M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032997 · Cited by 37
Self-citationPlastic compounds and liver diseases: Whether bisphenol A is the only culprit
Sangwan, S., Bhattacharyya, R., & Banerjee, D. (2024) · Liver International · doi:10.1111/liv.15879 · Cited by 36
“98 Dallio et al. have emphasized that BPA is associ - ated with many metabolic disorders and it appears to be playing a part at every step of NAFLD onset and progression.”
BackgroundMultisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease
Jiang, F., Wang, L., Ying, H., Sun, J., Zhao, J., Lü, Y., Bian, Z., Chen, J., Fang, A., Zhang, X., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.013 · Cited by 37
NAFLD prevalence and severity in overweight and obese populations
Francque, S., & Dirinck, E. L. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00375-2 · Cited by 36
Self-citationKrag, A. A., Buti, M., Lazarus, J. V., Allen, A. M., Bowman, J., Burra, P., Donnini, G., Duseja, A. K., El-Sayed, M. H., Gastaldelli, A., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.029 · Cited by 36
Self-citationFeng, G., Wong, V. W., Targher, G., Byrne, C. D., & Zheng, M. (2025) · Gut · doi:10.1136/gutjnl-2025-335542 · Cited by 37
“73 76”
Self-citationYu, R., Wang, Z., Ma, M., Xu, P., Liu, L., Tinkov, A. A., Lei, X. G., & Zhou, J. (2022) · Antioxidants · doi:10.3390/antiox11071263 · Cited by 37
“Antioxidants 2022, 11, 1263 5 of 20 Antioxidants 2022, 11, 1263 6 of 20 Note: DN, diabetic nephropathy; ELISA, enzyme-linked immunosorbent assay; GD, gestational diabetes; HG, hyperglycemia; HPLC, high-performance liquid chromatography; ICP-MS, inductively coupled plasma-mass spectrometry; MetS, metabolic syndrome; NA…”
BackgroundInfluentialAutophagy: A Cellular Guardian against Hepatic Lipotoxicity
Sinha, R. A. (2023) · Genes · doi:10.3390/genes14030553 · Cited by 35
“Nonalcoholic fatty liver disease (NAFLD), also known as metabolic associated fatty liver disease (MAFLD) [2], has become a global epidemic and is associated with other metabolic disorders, such as diabetes and obesity [3].”
BackgroundThe impact of public leadership on collaborative administration and public health delivery
din, M. Z. U., yuan, X. Y., Khan, N. U., & Estay, C. (2024) · BMC Health Services Research · doi:10.1186/s12913-023-10537-0 · Cited by 40
“The transition in the global economy and the dynamic environment have presented public health organizations with a challenge to enhance public health delivery [1].”
BackgroundOligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 35
Wang, Y., Ge, M.-X., Ran, S.-Z., Pan, X. Y., Chi, C., & Wang, B. (2025) · Marine Drugs · doi:10.3390/md23020063 · Cited by 36
“Nonalcoholic fatty liver disease (NAFLD) is a severe and widespread liver disease that is characterized by increased intrahepatic triglyceride (TG) and total cholesterol (TC) accumulation, steatosis, liver inflammation, hepatocellular damage, and progressive fibrosis [1,2].”
Deciphering the role of aberrant DNA methylation in NAFLD and NASH
Vachher, M., Bansal, S., Kumar, B., Yadav, S., & Burman, A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11119 · Cited by 34
Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD
An, L., Wirth, U., Koch, D. T., Schirren, M., Drefs, M., Koliogiannis, D., Nieß, H., Andrassy, J., Guba, M. O., Bazhin, A. V., et al. (2023) · Metabolites · doi:10.3390/metabo13010101 · Cited by 35
“NAFLD affects approximately one-quarter of the global adult population and carries a large economic burden [5].”
Desjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33
“The rising prevalence of both adult and childhood nonalcoholic fatty liver disease (NAFLD) poses immense burden on patients’ health-related quality of life and healthcare costs.(1) The advanced form of NAFLD—nonalcoholic steatohepatitis (NASH)—is typically characterized by liver steatosis, hepatocellular ballooning, a…”
Ivancovsky Wajcman, D., Byrne, C. J., Dillon, J. F., Brennan, P. N., Villota-Rivas, M., Younossi, Z. M., Allen, A. M., Crespo, J., Gerber, L. H., & Lazarus, J. V. (2026) · Hepatology · doi:10.1097/hep.0000000000001058 · Cited by 33
“[28,29] Although it does not feature meaningfully in any national or global non-communicable disease strategy, work published in 2023 identified critical priorities to advance the public health agenda for MASLD, given the pace of growth of its prevalence.”
Self-citationLong-term exposure to ambient PM2.5 and its constituents is associated with MAFLD
Guo, B., Huang, S., Li, S., Han, X., Lin, H., Li, Y., Qin, Z., Jiang, X., Wang, Z., Pan, Y., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100912 · Cited by 40
“The degree of liver fi brosis was evaluated by non-invasive test indices ( i.e. , APRI [aspartate aminotransferase-to-platelet ratio], FIB-4 [ fi brosis-4], and Forns index); the severity of metabolic disorders was assessed according to the number of major metabolic disorders (0 to 6).”
Sanyal, A. J., Husain, M., Diab, C., Mangla, K. K., Shoeb, A., Lingvay, I., & Tapper, E. B. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100386 · Cited by 42
“MASH is associated with a reduction in health-related quality of life and imposes a substantial healthcare burden [2,5].”
BackgroundInfluentialSelf-citationTsochatzis, E. A., Valenti, L. V. C., Thiele, M. S., Péloquin, S., Lazure, P., Masson, M. H., Allen, A. M., Lazarus, J. V., Noureddin, M., Rinella, M. E., et al. (2024) · Liver International · doi:10.1111/liv.15941 · Cited by 34
“10,48 However, they also suggest that significant gaps”
Self-citationPeng, D., Yu, Z., Wang, M., Shi, J., Sun, L., Zhang, Y., Zhao, W., Chen, C., Tang, J., Wang, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.935390 · Cited by 34
Zhang, J., Zhao, Y., Wang, S., Li, G., & Xu, K. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.018 · Cited by 33
Dalbeni, A., Lombardi, R., Henrique, M. K. C. L., Zoncapè, M., Pennisi, G., Petta, S., Tateishi, R., Keklikkıran, Ç., Colecchia, A., Sacerdoti, D., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000694 · Cited by 33
Self-citationNatural history of NAFLD: knowns and unknowns
Tsochatzis, E. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00565-8 · Cited by 33
Self-citationThe microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
“Metabolic disorders such as hyperglycemia, obesity, dyslipidemia, and hypertension are known contributors to the development of MASLD (4).”
Sedik, A. A., Elgohary, R., Khalifa, E., Khalil, W. K. B., Shafey, H. I., Shalaby, M. B., Gouida, M. S. O., & Tag, Y. M. (2024) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2023.2301344 · Cited by 34
“It is expected to affect approximately 23–25% of the overall adult population, with an annual incidence of 28-86/1000 person (Lazarus et al. 2022).”
BackgroundZhang, X.-L., Wang, T.-Y., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0048 · Cited by 33
“Last, but not least, putting NAFLD on the global public health and development agendas, and promoting NAFLD as a global public health issue is central [76], because there is a significant knowledge gap between liver specialists and non-liver specialists [77].”
BackgroundSelf-citationAlqahtani, S. A., Chan, W., & Yu, M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.019 · Cited by 32
Self-citationLazarus, J. V., Han, H., Mark, H. E., Alqahtani, S. A., Schattenberg, J. M., Soriano, J. B., White, T. M., Zelber‐Sagi, S., Dirac, M. A., & Collaborators, O. B. O. T. G. F. L. D. S. D. G. (2023) · Hepatology · doi:10.1097/hep.0000000000000361 · Cited by 32
“[25] Although health systems sit at the center of efforts to address the burden of fatty liver disease, tackling this public health challenge will require action well beyond the health sector.”
BackgroundSelf-citationLai, Y., He, Z., Liu, Y., Yin, X., Fan, X., Rao, Z., Fu, H., Gu, L., & Xia, T. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1231240 · Cited by 34
“…with NAFLD, effective dietary improvement, and achieving and maintaining at least 10% weight loss will undoubtedly significantly improve the prognosis of patients with NAFLD and have important implications for the maintenance of world health and the rational use of global healthcare resources (33).”
BackgroundPapatheodoridi, Μ., Pallini, G., Aithal, G. P., Lim, H. K., Cobbold, J., Torres, M. C. P., Misas, M. G., Ryan, J. D., Tomlinson, J., Allison, M. E., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.018 · Cited by 30
Self-citationMózes, F. E., Lee, J., Vali, Y., Selvaraj, E. A., Jayaswal, A. N. A., Boursier, J., de Lédinghen, V., Lupșor‐Platon, M., Yilmaz, Y. N., Chan, W., et al. (2024) · Liver International · doi:10.1111/liv.15914 · Cited by 35
“27,28 We provide details of the diagnostic performance of various thresholds for various screening strategies, and we demonstrate the trade-off between screen failure rates and the number of true-positive cases identified.”
Self-citationChen, M., Chen, Y., Lin, J.-Q., Hu, R., Liu, D., Chen, J., Li, K., & Jiang, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1421386 · Cited by 30
Antwi, S. O., Craver, E. C., Nartey, Y. A., Sartorius, K., & Patel, T. C. (2022) · Cancers · doi:10.3390/cancers14246234 · Cited by 30
“There is also a critical need to determine the proportion of HCC cases that are attributable to each of these metabolic risk factors to inform public health strategies for controlling or halting the increasing incidence of NAFLDrelated HCC [3,14].”
BackgroundOral nanomedicine biointeractions in the gastrointestinal tract in health and disease
Chen, C., Beloqui, A., & Xu, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115117 · Cited by 30
Cuño-Gómiz, C., de Gregorio, E., Tutusaus, A., Rider, P., Andrés-Sánchez, N., Colell, A., Morales, A., & Marí, M. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00569-w · Cited by 31
“…fatty liver disease (NAFLD) [22], defined by the presence of hepatic steatosis without causes for secondary hepatic fat accumulation [23], is the most common liver disease in Western countries, has a global prevalence of 25%, depending on the method of diagnosis, age, sex and ethnicity [24, 25].”
BackgroundIvashkin, V. T., Drapkina, O. M., Maevskaya, M. V., Raikhelson, K. L., Okovityi, S. V., Жаркова, М. С., Grechishnikova, V. R., Abdulganieva, D. I., Alekseenko, S. A., Ardatskaya, M. D., et al. (2025) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2025-35-1-94-152 · Cited by 31
Yang, N., Lu, Y., Liwen, C., & Lu, M. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24225 · Cited by 32
“According to the American Diabetes Association Criteria, a diagnosis of T2DM was made if any of the following conditions existed14: (1) Self- reported diabetes; (2) Using antidiabetic medicines; (3) Fasting plasma glucose ≥126 mg/dl (7 mmol/L);(4) Random plasma glucose ≥200 mg/dl (11.”
MethodThe effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Oh, H., Sohn, W., & Cho, Y. K. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0393 · Cited by 30
Egea, M. B., Filho, J. G. D. O., & Lemes, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512015 · Cited by 35
“MetS is a public health concern because it is globally highly prevalent and is associated with several health conditions [22].”
BackgroundHuang, L., Zeng, Y., Li, F., Zheng, X., Rao, Q., Gajendran, B., Varier, K. M., Peng, T., & Tang, L. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105715 · Cited by 29
Mantovani, A., Morieri, M. L., Palmisano, L., Masulli, M., Cossu, E., Baroni, M. G., Bonomo, K., Cimini, F. A., Cavallo, M. G., Buzzetti, R., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01945-x · Cited by 32
“It is well known that NAFLD is a growing public health problem in people with T2DM, causing considerable healthcare costs, economic losses, and reduced health-related quality of life [1].”
BackgroundAllen, A. M., Charlton, M., Cusi, K. J., Harrison, S. A., Kowdley, K. V., Noureddin, M., & Shubrook, J. H. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2325332 · Cited by 29
“Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important driver of chronic liver disease world-wide [1], and is associated with a considerable healthcare and socioeconomic burden and reduced health-related quality of life [2,3].”
BackgroundSelf-citationLiu, J., Inchingolo, R., Suryawanshi, P. B., Guo, B., Kurepa, D., González, R., Yan, W., Chi, J., Acosta, C. M., Jagła, M., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03879-5 · Cited by 28
“%) agreement, ‘A’ denotes 90–99% agreement, ‘B’ denotes 78–89% agreement, and ‘C’ denotes 67–77% agreement [34–37].”
Identification of high-risk subjects in nonalcoholic fatty liver disease
Stern, C., & Castéra, L. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0431 · Cited by 29
“In addition, NAFLD is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity.(57) Therefore, dissemination of guidelines on the use of non-invasive tests and multidisciplinary approaches are critical to increase awareness and to improve management of…”
BackgroundXiao, L., Xiong, H., Deng, Z., Peng, X. X., Cheng, K., Zhang, H., Jiang, L., & Sun, Y. (2023) · Food & Function · doi:10.1039/d2fo03028d · Cited by 29
Zhang, Y., Fu, Q., Wu, T., Liu, K., Xiao, Y., Liao, Q., Qi, X., Li, Y., & Zhou, L. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.093 · Cited by 28
Țâru, M.-G., Neamți, L., Țâru, V., Procopciuc, L. M., Procopeț, B., & Lupșor‐Platon, M. (2023) · Diagnostics · doi:10.3390/diagnostics13040788 · Cited by 31
“Identifying its advanced stages (≥F3) among patients with NAFLD and NASH is of outmost importance [21].”
BackgroundNanodrug Delivery Systems for Metabolic Chronic Liver Diseases: Advances and Perspectives
Athanasopoulou, F., Manolakakis, M., Vernia, S., & Kamaly, N. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0261 · Cited by 30
Mouskeftara, T., Deda, O., Papadopoulos, G., Chatzigeorgiou, A., & Gika, H. (2024) · Molecules · doi:10.3390/molecules29071494 · Cited by 28
“Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the most common forms of chronic liver disease and has evolved into a significant health issue worldwide [1].”
BackgroundImpact of NAFLD and Fibrosis on Adverse Cardiovascular Events in Patients With Hypertension
Huang, Y., Wan, T., Hong, Y., Wang, X., Jiang, X., Yang, Y., Gao, H., Ji, J., Wang, L., Yang, Y., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.24252 · Cited by 27
Protective Effect and Mechanism of Plant-Based Monoterpenoids in Non-alcoholic Fatty Liver Diseases
Zhang, W., Lin, H., Cheng, W., Huang, Z., & Zhang, W. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c00744 · Cited by 28
RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
Wang, Y., Tai, Y., Way, G. W., Zeng, J., Zhao, D., Su, L., Jiang, X., Jackson, K. G., Wang, X., Gurley, E. C., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00910-7 · Cited by 29
“Background Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases that affect more than 25% of the adult population globally, imposing a substantial social and economic burden [1].”
Bioactive Compounds from Brown Algae Alleviate Nonalcoholic Fatty Liver Disease: An Extensive Review
Wu, Y., Jin, X., Zhang, Y., Liu, J., Wu, M., & Tong, H. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06578 · Cited by 27
Nonalcoholic fatty liver disease from a primary care perspective
Clark, J. M., Cryer, D. R. H., Morton, M., & Shubrook, J. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15016 · Cited by 27
“Patients and patient organizations should be actively involved in developing strategies to improve the management of NAFL and NASH.45 There is also a need for better education, effective communica- tion and emotional support of patients at the time of diagnosis and at subsequent appointments.51 Patients require advice…”
BackgroundSelf-citationLv, T., Xiong, X., Yan, W., Liu, M., Xu, H., & He, Q. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1325 · Cited by 26
Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.
Mori, T., Yoshio, S., Kakazu, E., & Kanto, T. (2024) · PubMed Central · doi:10.1093/gastro/goae089 · Cited by 30
Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East Region
Ong, J. P., Alswat, K., Hamid, S. S., & El‐Kassas, M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.014 · Cited by 26
Self-citationGaucher, J., Montellier, E., Vial, G., Chuffart, F., Guellerin, M., Bouyon, S., Lemarié, E., Yamaryo‐Botté, Y., Dirani, A., Messaoud, R. B., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108837 · Cited by 25
Metadata
- Authors
- Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., Francque, S., George, J., Hagström, H., Huang, T. T.-K., Ismail, M. H., Kautz, A., Sarin, S. K., Loomba, R., Miller, V., Newsome, P. N., Ninburg, M., Ocama, P., Ratziu, V., Rinella, M., Romero, D., Romero-Gómez, M., Schattenberg, J. M., Tsochatzis, E. A., Valenti, L., Wong, V. W.-S., Yilmaz, Y., Younossi, Z. M., Zelber-Sagi, S., the NAFLD Consensus Consortium, Åberg, F., Adams, L., Khatry, M. S. A., Naamani, K. A., Murillo, O. A., Allen, A. M., Alnaser, F., Alqahtani, S. A., Alswat, K., Alvaro, D., Andrade, R. J., Arrese, M., Awuku, Y. A., Ayesha, M., Baatarkhuu, O., Bakieva, S., Basu, R., Bataller, R., Bedri, S., Bosi, E., Bourliere, M., Bruha, R., Bugianesi, E., Burra, P., Buti, M., Byrne, C. D., Calleja, J. L., Carrieri, P., Carter, F., Fernandez, M. I. C., Castillo-Lopez, G., Castro-Narro, G. E., Chan, H. L. Y., Chan, W.-K., Chang, Y., Colombo, M., Coppell, K. J., Corey, K., Craxi, A., Cryer, D., Dassanayake, A., Martins, A. D. A. S., de Ledinghen, V., DelPrato, S., Demaio, A., Desalegn, H., Dillon, J., Duseja, A., Dorairaj, P., Ekstedt, M., El Kassas, M., Elsanousi, O. M., Esmat, G., Fan, J.-G., Farpour-Lambert, N., Flisiak, R., Fouad, Y., Fuchs, M., Gani, R. A., Gerber, L., Ghazinyan, H., Gheorghe, L., Goh, G. B.-B., Grønbæk, H., Gulnara, A., Hamid, S., Hebditch, V., Hickman, I. J., Hocking, S. L., Hunyady, B., Idilman, R., Isakov, V. A., Jamal, M. H., Jepsen, P., Iskandar, N. J., Song, M. J., Sudhamshu, K. C., Kakizaki, S., Kalamitsis, G., Kanwal, F., Kao, J.-H., Kaplan, L., Kawaguchi, T., Khader, Y., Kim, S. U., Kodjoh, N., Koek, G., Koike, K., Komas, N. P., Korenjak, M., Kugelmas, M., Labidi, A., Lange, N. F., Lavine, J. E., Lazo, M., Lee, N., Lesmana, C. R. A., Liu, C.-J., Long, M. T., Lopez-Jaramillo, P., Malekzadeh, R., Mahtab, M. A., Marchesini, G., Marinho, R., Vázquez, S. E. M., Mateva, L., Nlombi, C. M., Melin, P., Mikolasevic, I., Milovanovic, T., Musso, C., Nakajima, A., Nava, E., Nersesov, A. V., Nikolova, D., Norris, S., Novak, K., Oben, J., Ong, J. P., Onyekwere, C., Papatheodoridis, G., Paruk, I., Patel, K., Macedo, M. P., Penha-Gonçalves, C., Figueroa, M. P., Hofmann, W. P., Petta, S., de Oliveira, C. P. M. S., Puri, P., Pan, C. Q., Rac, M., Ralston, J., Ramji, A., Razavi, H., Alvares-da-Silva, M. R., Roberts, S., Roden, M., Rose, T., Rouabhia, S., Rovere-Querini, P., Rowe, I. A., Sadirova, S., Salupere, R., Saparbu, T., Sayegh, R., Sebastiani, G., Seki, Y., Selmo, J., Serme, A. K., Shaw, J. E., Shenoy, T., Sheron, N., Shibolet, O., Silva, M., Skrypnyk, I., Socha, P., Soriano, J., Spearman, C. W., Sridharan, K., Suárez, J. J., Sheriff, D. S., Sung, K.-C., Swain, M., Tacke, F., Taheri, S., Tan, S.-S., Tapper, E. B., Yki-Järvinen, H., Thiele, M., Shawa, I. T., Tolmane, I., Torres, E. A., Trauner, M., Treeprasertsuk, S., Turcanu, A., Valantinas, J., Vesterhus, M., Waked, I., Wild, S. H., Willemse, J., Wong, R. J., Xanthakos, S., Young, D. Y., Yu, M.-L., Zheng, K. I., Zeybel, M., & Zheng, M.-H.
- Affiliations
- Barcelona Institute for Global Health (ES)
- European Association for the Study of the Liver (CH)
- NIHR Newcastle Biomedical Research Centre (GB)
- Pontificia Universidad Católica de Chile (CL)
- University College London Hospitals NHS Foundation Trust (GB)
- Marqués de Valdecilla University Hospital (ES)
- Veterans Health Administration (US)
- University of Washington (US)
- University of Antwerp (BE)
- The University of Sydney (AU)
- Karolinska Institutet (SE)
- City University of New York (US)
- King Fahd Hospital of the University (SA)
- Institute of Liver and Biliary Sciences (IN)
- University of California San Diego (US)
- University of California, Berkeley (US)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Makerere University (UG)
- Université Paris Cité (FR)
- Northwestern University (US)
- The Graduate Center, CUNY (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- The Royal Free Hospital (GB)
- University of Milan (IT)
- Chinese University of Hong Kong (HK)
- Marmara University (TR)
- Inova Health System (US)
- University of Helsinki (FI)
- The University of Western Australia (AU)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- King Saud University (SA)
- Sapienza University of Rome (IT)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- University of Health and Allied Sciences (GH)
- University of KwaZulu-Natal (ZA)
- Mongolian National University of Medical Sciences (MN)
- Ministry of Health of the Republic of Uzbekistan (UZ)
- University of Virginia (US)
- University of Pittsburgh (US)
- Ahfad University for Women (SD)
- Vita-Salute San Raffaele University (IT)
- University of Turin (IT)
- University of Padua (IT)
- University of Southampton (GB)
- Inserm (FR)
- University of the West Indies (BS)
- Universidad de Buenos Aires (AR)
- Union Hospital (HK)
- University of Malaya (MY)
- Kangbuk Samsung Hospital (KR)
- IRCCS Ospedale San Raffaele (IT)
- University of Otago (NZ)
- Harvard University (US)
- University of Kelaniya (LK)
- University of Pisa (IT)
- St. Paul's Hospital Millennium Medical College (ET)
- University of Dundee (GB)
- Post Graduate Institute of Medical Education and Research (IN)
- World Heart Federation (CH)
- Linköping University (SE)
- National Ribat University (SD)
- Cairo University hospitals (EG)
- Shanghai Jiao Tong University (CN)
- Medical University of Białystok (PL)
- Minia University (EG)
- Virginia Commonwealth University (US)
- University of Indonesia (ID)
- Carol Davila University of Medicine and Pharmacy (RO)
- Singapore General Hospital (SG)
- Aarhus University Hospital (DK)
- Aga Khan University (PK)
- British Liver Trust (GB)
- Princess Alexandra Hospital (AU)
- Kuwait University (KW)
- Hlabisa Hospital (ZA)
- Catholic University of Korea (KR)
- National Academy of Medical Sciences (NP)
- National Hospital Organization Takasaki General Medical Center (JP)
- Baylor College of Medicine (US)
- National Taiwan University Hospital (TW)
- Kurume University (JP)
- Jordan University of Science and Technology (JO)
- Yonsei University (KR)
- Université d'Abomey-Calavi (BJ)
- Maastricht University Medical Centre (NL)
- The University of Tokyo (JP)
- Institut Pasteur de Bangui (CF)
- Denver Public Library (US)
- Hôpital La Rabta (TN)
- University Hospital of Bern (CH)
- Columbia University (US)
- Drexel University (US)
- Wilton Park (GB)
- Boston University (US)
- University of Tehran (IR)
- Bangladesh Medical University (BD)
- University of Bologna (IT)
- Centro Hospitalar Lisboa Norte (PT)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- University Hospital St. Ivan Rilski (BG)
- University of Kinshasa (CD)
- Favaloro Foundation (AR)
- Yokohama City University (JP)
- Universidad Autónoma de Nuevo León (MX)
- Ss. Cyril and Methodius University in Skopje (MK)
- St. James's Hospital (IE)
- Ljubljana University Medical Centre (SI)
- Guy's Hospital (GB)
- University of the Philippines Manila (PH)
- Lagos State University (NG)
- National and Kapodistrian University of Athens (GR)
- University Health Network (CA)
- Universidade Nova de Lisboa (PT)
- University of Palermo (IT)
- NYU Langone Health (US)
- World Obesity Federation (GB)
- University of British Columbia (CA)
- Center for Disease Analysis (US)
- Alfred Health (AU)
- Düsseldorf University Hospital (DE)
- University of Leeds (GB)
- Tartu University Hospital (EE)
- Kyrgyz State Medical Academy (KG)
- Saint Joseph University (LB)
- McGill University Health Centre (CA)
- Yotsuya Medical Cube (JP)
- Baker Heart and Diabetes Institute (AU)
- King's College London (GB)
- Tel Aviv University (IL)
- Children's Memorial Health Institute (PL)
- Hospital Universitario de La Princesa (ES)
- University of Cape Town (ZA)
- Arabian Gulf University (BH)
- Universidad San Francisco de Quito (EC)
- University of Calgary (CA)
- Charité – Universitätsmedizin Berlin (DE)
- Weill Cornell Medical College in Qatar (QA)
- Hospital Selayang (MY)
- University of Michigan (US)
- University of Southern Denmark (DK)
- University of Malawi (MW)
- Riga East University Hospital (LV)
- University of Puerto Rico, Medical Sciences Campus (PR)
- Medical University of Vienna (AT)
- Chulalongkorn University (TH)
- Nicolae Testemițanu State University of Medicine and Pharmacy (MD)
- Vilnius University Hospital Santariskiu Klinikos (LT)
- Haraldsplass Diakonale Sykehus (NO)
- National Liver Institute (EG)
- University of Edinburgh (GB)
- Stanford Medicine (US)
- Cincinnati Children's Hospital Medical Center (US)
- National University of Singapore (SG)
- Kaohsiung Medical University (TW)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Koç University (TR)
- Corresponding author
- Lazarus, Jeffrey V.
- ORCID
- Lazarus, Jeffrey V.
- Mark, Henry E.
- Anstee, Quentin M.
- Arab, Juan Pablo
- Batterham, Rachel L.
- Castera, Laurent
- Cortez-Pinto, Helena
- Crespo, Javier
- Cusi, Kenneth
- Dirac, M. Ashworth
- Francque, Sven
- George, Jacob
- Hagström, Hannes
- Huang, Terry T.-K.
- Ismail, Mona H.
- Sarin, Shiv Kumar
- Loomba, Rohit
- Miller, Veronica
- Newsome, Philip N.
- Ninburg, Michael
- Ocama, Ponsiano
- Ratziu, Vlad
- Rinella, Mary
- Romero, Diana
- Romero-Gómez, Manuel
- Schattenberg, Jörn M.
- Tsochatzis, Emmanuel A.
- Valenti, Luca
- Wong, Vincent Wai-Sun
- Yilmaz, Yusuf
- Younossi, Zobair M.
- Åberg, Fredrik
- Adams, Leon
- Naamani, Khalid Al
- Allen, Alina M.
- Alqahtani, Saleh A.
- Alswat, Khalid
- Alvaro, Domenico
- Andrade, Raúl J.
- Arrese, Marco
- Awuku, Yaw Asante
- Baatarkhuu, Oidov
- Bakieva, Shokhista
- Basu, Rita
- Bataller, Ramon
- Bedri, Shahinaz
- Bosi, Emanuele
- Bugianesi, Elisabetta
- Burra, Patrizia
- Byrne, Christopher D.
- Carrieri, Patrizia
- Chan, Henry Lik Yuen
- Chan, Wah-Kheong
- Chang, Yoosoo
- Colombo, Massimo
- Coppell, Kirsten J.
- Corey, Kathleen
- Cryer, Donna
- Dassanayake, Anuradha
- Desalegn, Hailemichael
- Dillon, John
- Duseja, Ajay
- Ekstedt, Mattias
- Elsanousi, Osama M.
- Esmat, Gamal
- Fan, Jian-Gao
- Flisiak, Robert
- Fouad, Yasser
- Fuchs, Michael
- Gani, Rino A.
- Gerber, Lynn
- Gheorghe, Liana
- Goh, George Boon-Bee
- Grønbæk, Henning
- Hamid, Saeed
- Hickman, Ingrid J.
- Hocking, Samantha L.
- Jamal, Mohammad H.
- Jepsen, Peter
- Song, Myeong Jun
- Kakizaki, Satoru
- Kanwal, Fasiha
- Kao, Jia-Horng
- Kaplan, Lee
- Kawaguchi, Takumi
- Khader, Yousef
- Kim, Seung Up
- Kodjoh, Nicolas
- Koek, Ger
- Koike, Kazuhiko
- Komas, Narcisse Patrice
- Korenjak, Marko
- Kugelmas, Marcelo
- Labidi, Asma
- Lange, Naomi F.
- Lavine, Joel E.
- Lazo, Mariana
- Lee, Nancy
- Lesmana, Cosmas Rinaldi A.
- Liu, Chun-Jen
- Long, Michelle T.
- Malekzadeh, Reza
- Mahtab, Mamun Al
- Marchesini, Giulio
- Marinho, Rui
- Vázquez, Sophia E. Martínez
- Nlombi, Charles Mbendi
- Musso, Carla
- Nakajima, Atsushi
- Norris, Suzanne
- Oben, Jude
- Ong, Janus P.
- Onyekwere, Charles
- Papatheodoridis, George
- Paruk, Imran
- Patel, Keyur
- Macedo, M. Paula
- Figueroa, Marlene Pérez
- Hofmann, Wolf Peter
- Petta, Salvatore
- Puri, Puneet
- Pan, Calvin Q.
- Ralston, Johanna
- Ramji, Alnoor
- Razavi, Homie
- Roberts, Stuart
- Roden, Michael
- Rowe, Ian A.
- Sadirova, Shakhlo
- Sebastiani, Giada
- Seki, Yosuke
- Shaw, Jonathan E.
- Sheron, Nick
- Shibolet, Oren
- Silva, Marcelo
- Socha, Piotr
- Soriano, Joan
- Spearman, C. Wendy
- Sridharan, Kannan
- Sheriff, Dhastagir Sultan
- Sung, Ki-Chul
- Swain, Mark
- Tacke, Frank
- Taheri, Shahrad
- Tan, Soek-Siam
- Tapper, Elliot B.
- Thiele, Maja
- Shawa, Isaac Thom
- Tolmane, Ieva
- Torres, Esther A.
- Trauner, Michael
- Treeprasertsuk, Sombat
- Turcanu, Adela
- Valantinas, Jonas
- Vesterhus, Mette
- Waked, Imam
- Wild, Sarah H.
- Wong, Robert J.
- Xanthakos, Stavra
- Yu, Ming-Lung
- Zheng, Kenneth I.
- Zheng, Ming-Hua
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2021-10-27
- Volume
- 19
- Issue
- 1
- Pages
- 60-78
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3208129759
- Cited by
- 757
- References
- 193
- Citations by year
- 2026: 100 · 2025: 156 · 2024: 163 · 2023: 201 · 2022: 127 · 2021: 9
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Falk Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Celgene
- City University of New York
- Medpace
- Regeneron Pharmaceuticals
- European Federation of Pharmaceutical Industries and Associations
- Arrowhead Pharmaceuticals
- Medicines Company
- Galecto
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Coherus Biosciences
- National Institute for Health and Care Research (RP-2015-06-005)
- Rosetrees Trust
- Novo Nordisk
- Astellas Pharma
- Shionogi
- European Association for the Study of the Liver
- Novo Nordisk Fonden (NNF18OC0054612)
- Servier
- Julius Clinical
- Genentech
- Allergan
- Novartis Pharma
- Takeda Pharmaceuticals International
- Sanofi-Aventis Deutschland
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, public health policy, global health agenda, metabolic syndrome, non-communicable diseases, obesity, health system response, Delphi consensus
- MeSH terms
- Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.